MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma
Multiple myeloma (MM), a clonal B-cell malignancy with accumulation of plasma cells in the bone marrow, accounts for more than 10% of all hematological malignancies. Despite use of high-dose therapy followed by autologous stem cell transplantation, median survival has not improved beyond 4-5 years, and even tandem autografts do not offer the prospect of a cure. 1 Although therapeutic benefit of allogeneic transplantation comes at the expense of significant treatment-related toxicity, the detection of a graft-versus-myeloma effect exerted by donorderived T cells has demonstrated that MM cells are susceptible to cellular immunity. The efficacy and safety of myeloma-specific immunotherapy will, however, depend on the identification of antigens that are selectively expressed on tumor cells.
Among the currently known groups of tumor antigens, one of the most relevant for the development of cancer vaccines is the cancer-testis (CT) antigens. Originally discovered in cancer patients, these antigens may elicit specific cellular and humoral immune responses. 2 Expression of these antigens is restricted to germline cells and a broad variety of tumor cells, including malignant plasma cells. [3] [4] [5] In patients with MM, however, various immunological deficiencies were recently described. 6 Broad humoral immune responses against CT antigens were mainly shown after allogeneic transplantation, suggesting low spontaneous immunogenicity in MM. 5 We assessed specific humoral responses directed against CT7, NY-ESO-1, MAGE-A3, and SSX-2 in 60 patients with previously treated stage I-III MM (Durie-Salmon Staging System). In order to test the humoral response, the CT-genes were cloned from a MM cell line (U266), then cloned in an expression vector and the proteins produced in Escherichia coli; after purification the proteins have been sequenced by mass spectrometry (data not shown) as previously described. 5 The CT7 protein has been for the first time produced and tested for humoral response; the coding region (CT7-fl) was amplified with primers (5 0 FW-ATGG GGGACAAGGATATGCCTAC; 5 0 RV-TCACTCAGAAGAGAAG CTGGGGG) using Phusion Polymerase (Finnzymes, Helsinki, Finland) from an MM cell line (U266) and cloned into pQE32 expression vector (Qiagen, Hombrechtikon, Switzerland). In total, 100 sera from 60 patients were analyzed. The assays were performed at least three times for all sera, as previously described. 7 Whereas none of the 18 healthy donors showed any specific antibody (Ab) responses (data not shown), specific IgG responses toward at least one CT antigen were detected in 30 of 60 patients. The most commonly detected Ab response was directed against CT7 (30 of 60 patients or 50%; Figure 1a ). In contrast, humoral immune responses against SSX-2, MAGE-A3 and NY-ESO-1 were considerably less frequent (1, 1 and 2 patients, respectively). There was no correlation between the presence of specific Ab responses and tumor stage or distinct clinico-pathogenic subgroups. Serum reactivity against the recombinant CT7 protein was confirmed using native CT7 protein immunoprecipitated from the cell line U266 with mAbCT7-33 (DAKO, Baar, Switzerland; Figure 1b) . Interestingly, two out of four patients with monoclonal gammopathy of unknown significance (MGUS) exhibited humoral immune responses against CT7 (data not shown). This preliminary observation may indicate that the immune system of patients with premalignancies is capable of targeting CT antigens expressed by tumor progenitors. From 24 patients, bone marrow biopsies were available to determine CT7 protein expression by immunohistochemical staining of whole-tissue sections of bone marrow, using mAbCT7-33 and anti-NY-ESO-1 Ab E978 (clone E978; Zymed Laboratories, San Francisco, CA, USA). Using a tissue microarray approach, we observed CT7 expression in the majority of samples (14 of 24 samples, 58%, data not shown); this suggests frequent and consistent expression, in agreement with previously published work.
4,5 CT7 Ab responses were present in 13 of 14 (93%) patients with CT7-expressing myeloma cells. Furthermore, we observed NY-ESO-1 expression in 1 out of 24 lesions (4%) of MM patients; this is in line with a previous study, 5 and may explain the considerably lower number of patients exhibiting Ab responses against NY-ESO-1. To further explore the immunogenicity of particular protein sites, we synthesized N-and C-terminal fragments of CT7 by deleting the gene from position 1563 bp to the stop codon (CT7 1À521 ) and from position 1-1563 bp (CT7 522À1142 ). These constructs were tested for reactivity in CT7 Ab-positive patients' sera with MM (30 patients) and MGUS (two patients). Six patients (19%) exhibited reactivity only toward CT7 1À521 , 16 patients (50%) had reactivity only towards CT7 522À1142 , and 10 (31%) had reactivity towards both protein fragments (Figure 2a) . Therefore, we observed heterogeneity among sera, indicating presence of several B-cell epitopes, as has been reported for other tumor antigens. 7 However, data show that CT7 522À1142 is the preferential target of the CT7 Ab response.
Subsequently, we assessed serum Ab titers during the clinical course and explored whether changes in Ab titers correlate with clinical events. While titers against uninvolved IgGs (for example, IgG HSV-1) as a measure of humoral immunity remains stable, we noticed fluctuations of anti-CT7 titer during the course of disease (Figure 2b) . In fact, a decrease in CT7 Ab titer was found in patient ZH-377, who achieved a major response after tandem high-dose therapy between July 2004 and June 2005. An increasing CT7 Ab titer was observed in patient ZH-130, who showed progressive disease under treatment with thalidomide ( Figure 2b) . Similar results were obtained in two other patients (data not shown). We hypothesize that the immune response to the CT7 protein that may be released from tumor cells and presented to immune cells, is dependent on the level and the persistence of the antigenic stimulus. Similar observations were made previously for other tumor antigens such as NY-ESO-1. 8 The present study demonstrates the immunogenicity of CT7 in vivo, which leads to high frequency of specific IgG Abs in patients with MM. This observation is intriguing, since recent work suggests an underlying alteration in anti-myeloma immunity. 6 Hence, the observed specific immune responses against CT7 underline that anti-myeloma immunity may be generated in patients and may overcome at least in part those immunomodulatory mechanisms. On the basis of the observed close association between T-cell reactivity and NY-ESO-1 Ab status, 8 the presence of spontaneous Ab responses toward CT7 suggests that there may already exist a reservoir of CT7-specific T cells. Importantly, those T cells may be targeted in active immunotherapy approaches. To further understand the clinical relevance of integrated anti-myeloma immune responses, it will be important to dissect the specific T-cell response against CT7 in patients with monoclonal gammopathies.
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